“We like pharma as a sector because we think there is earning resilience in the sector. And more importantly, the sector is coming out of two years or three years of underperformance and business challenges. And now a lot of those headwinds which the sector faced has turned into tailwinds.”
“Birlasoft has seen a CEO change about three quarters back. We think the new CEO in-charge is clearly very driven and given the background and track record he brings with him, he can clearly change the growth velocity and growth trajectory of the company for the foreseeable future. Likewise, Tech Mahindra is undergoing a CEO change after almost 20 years.”
“For someone who is invested in railway and defence stocks, it is not a bad idea to take some money off the table because stocks have moved very significantly and we have seen gains that are 200-300-400% over the last 9 to 12 months.” From a relative basis we find much more value in IT and pharma and we are clearly taking money off of some of these sectors which have done exceedingly well over the last let us say 18 months which is essentially financials and capital goods and putting that money to work into IT and pharma.
"While the adoption of AI solutions was currently limited to small applications, bigger deals would become more commonplace over the next few years. Comparing the enthusiasm surrounding the adoption of the technology to the launch of initial public offerings, Murarka said "the sector offered credible and exciting opportunities over a medium- to long-term perspective."
"The initial euphoria that will surround the listing of Jio Financial will settle over the next four to six weeks, during which Jio Financial stocks might move from weaker hands to stronger ones. It is only a matter of time before the retail and Jio demergers follow. While Jio is expected to be amongst the leading financial players for different segments of financials in 10 years, investors should still wait for a while before buying it."